Welcome to our dedicated page for IPSEN SA news (Ticker: IPSEY), a resource for investors and traders seeking the latest updates and insights on IPSEN SA stock.
Ipsen SA (ADR: IPSEY) generates a steady flow of news centered on its activities as a global, mid-sized biopharmaceutical company focused on Oncology, Rare Disease and Neuroscience. This news page aggregates company announcements, partner releases and regulatory updates that mention Ipsen and its ADR program, giving readers a focused view of developments that can influence perceptions of IPSEY.
Recent news highlights Ipsen’s role in advancing specialty care medicines. In oncology, the company has reported Phase III NAPOLI 3 trial results for an investigational Onivyde-based regimen (NALIRIFOX) in previously untreated metastatic pancreatic ductal adenocarcinoma, with statistically significant improvements in overall and progression-free survival compared to a nab-paclitaxel plus gemcitabine regimen. Ipsen has also nominated a first clinical drug candidate from its multi-year oncology collaboration with Marengo Therapeutics, based on Marengo’s STAR T cell activator platform for solid tumors.
In rare diseases, news items cover Ipsen’s work in pediatric cholestatic liver diseases and ultra-rare conditions. Examples include Health Canada’s approval of Bylvay (odevixibat) for pruritus due to Progressive Familial Intrahepatic Cholestasis, under a partnership with Medison Pharma, and regulatory interactions for palovarotene in fibrodysplasia ossificans progressiva, including a CHMP negative opinion and a U.S. FDA Complete Response Letter. Corporate news also details Ipsen’s agreement to acquire Albireo, adding Bylvay and other bile acid modulators to its rare disease portfolio.
Neuroscience and rare neurological disease updates feature Ipsen’s collaboration with Skyhawk Therapeutics to discover RNA-targeting small molecules for rare neurological diseases. Partner announcements describe Ipsen’s option to obtain exclusive global rights to development candidates and its responsibility for later-stage development and commercialization.
Investors and observers can use this news feed to follow Ipsen’s clinical trial readouts, regulatory decisions, licensing deals, acquisitions and capital markets disclosures that reference IPSEY. Regularly reviewing these updates can help contextualize the company’s therapeutic focus and strategic direction as reflected in public announcements.
Ipsen has reported its share capital details as of February 28, 2022. The company has a total of 83,814,526 shares, resulting in a gross total of 132,100,358 voting rights. The net total of voting rights stands at 130,837,209, considering the deduction of shares without voting rights. This announcement adheres to the French Commercial Code and regulations established by the Autorité des Marchés Financiers.
Ipsen presented new data at the ENETS 2022 conference, highlighting the benefits of Somatuline Autogel/Somatuline Depot (lanreotide) over octreotide in patients with gastroenteropancreatic neuroendocrine tumors. The PRESTO 2 survey showed significantly fewer patients experienced injection-site pain lasting over two days with Somatuline (6.0%) vs. octreotide (22.8%). Additionally, HomeLAN survey participants reported high satisfaction (95.5%) with their at-home injection experience, indicating improved patient control and comfort in treatment.
Ipsen announced the appointment of Catherine Abi-Habib as EVP Strategy, Transformation, and Digital, effective March 1, 2022. She replaces Dominique Bery, who will head the Nordics & Baltics. With over 10 years of experience in life sciences, she previously worked at McKinsey, specializing in performance transformation. CEO David Loew emphasized her expertise in digital innovation as key to Ipsen's strategy. Ipsen reported €2.9bn in sales in FY 2021 and operates globally in oncology, rare diseases, and neuroscience.
Ipsen announced updated two-year results from the Phase III CheckMate -9ER trial, demonstrating significant efficacy of Cabometyx (cabozantinib) combined with Opdivo (nivolumab) for advanced renal cell carcinoma (aRCC). Follow-up data showed improved overall survival (37.7 months) and progression-free survival (16.6 months) compared to sunitinib. The safety profile remained consistent, with 97.2% experiencing treatment-related adverse events. Patients reported enhanced health-related quality of life benefits. The results will be presented at the ASCO GU symposium from February 17-19, 2022.
Ipsen reported robust FY 2021 results with total sales of €2.87bn, up 10.7% as reported and 12.3% at constant currency. Core operating margin improved to 35.2%, with net profit at €646.7m, a 17.8% increase. The company plans to divest its Consumer Healthcare business, valued at up to €350m, to focus on Specialty Care, which constituted 92.1% of sales. Guidance for FY 2022 anticipates over 2% sales growth, excluding Consumer Healthcare, with an updated outlook projecting a 4-6% CAGR from 2020-2024. A proposed dividend of €1.20 per share reflects a 20% increase from the previous year.
Ipsen reported on January 31, 2022, the total number of shares and voting rights regarding its share capital. The company has 83,814,526 shares outstanding, with a gross total of 132,120,082 voting rights and a net total of 130,802,629 voting rights. This update follows provisions under the French Commercial Code regarding voting rights disclosures. The gross total accounts for shares with double voting rights and treasury shares, whereas the net total excludes shares without voting rights.
Ipsen has received Health Canada approval for Sohonos (palovarotene capsules), the first treatment for fibrodysplasia ossificans progressiva (FOP), enabling chronic use and flare-up management for patients aged 8 and above. This marks Sohonos' first global approval, following the MOVE trial which evaluated its efficacy in reducing new bone formation. Ipsen plans to file for U.S. approval in H1 2022 and is in discussions with other global regulators. FOP is an ultra-rare genetic disorder affecting 1.36 per million individuals.
Ipsen (Euronext: IPN; ADR: IPSEY) has appointed Karen Witts as an independent member of its Board of Directors. Witts previously served as Group CFO at Compass Group Plc until October 2021, and has extensive experience in corporate finance, strategy, and risk management from her tenures at companies like Kingfisher Plc and Vodafone. This addition brings the board to fourteen directors, which includes six women. The upcoming Shareholders' Meeting in 2022 will seek approval for Witts' position, covering the term until 2025.
As of December 31, 2021, IPSEN's liquidity agreement with NATIXIS ODDO BHF reported a liquidity account holding 34,053 shares and €1,433,400.74. Initially, 12,751 shares and €3,137,935 were allocated when the agreement commenced. Between July 1 and December 31, 2021, a total of 1,350 buy and 1,425 sell transactions occurred, with trading volumes of 178,366 shares (€15,275,528.42) bought and 168,568 shares (€14,644,572.90) sold. IPSEN is a global biopharmaceutical company focused on Oncology, Neuroscience, and Rare Diseases, with sales exceeding €2.5bn in FY 2020.
This press release from Ipsen provides regulatory updates regarding its share capital and voting rights as of December 31, 2021. The total number of shares composing the share capital amounts to 83,814,526, while the gross total of voting rights is 132,125,842, and the net total of voting rights stands at 130,808,311. These figures are crucial for shareholders and potential investors, reflecting the company’s governance structure and compliance with French financial regulations.